- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07312500
Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer
December 30, 2025 updated by: Dazhi Xu, Fudan University
Application of Fecal DNA Methylation and Fecal Helicobacter Pylori Gastric Cancer Susceptibility Genes in Clinical Diagnosis, Treatment, and Relapse and Metastasis of Gastric Cancer
Based on the detection technology of methylation sites in feces, combined or not combined with Helicobacter pylori gastric cancer susceptibility gene detection, an early diagnosis and detection system for gastric cancer is established, and the clinical diagnostic value of the detection system is evaluated.
In addition, the study observed the association between different loci and post-treatment recurrence, metastasis, or long-term survival rate through long-term follow-up of gastric cancer patients; Follow up with individuals with benign diseases such as gastritis and healthy individuals, compare cases of gastric cancer, and compare their sample data during follow-up with controls who did not have the disease.
Study Overview
Status
Active, not recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shanghai, China
- Fudan University Shanghai Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Probability Sample
Study Population
Subjects for this clinical study were obtained from inpatients and outpatient follow-up patients attending the sub-center.
Subjects will be identified by the investigator based on subject entry criteria and informed of the contents of the informed consent form.
Subjects will have their feces collected at the time of clinic visit or at the time of physical examination and will be tested for fecal methylated DNA and H. pylori gastric cancer susceptibility genes.
Description
Inclusion Criteria:
- Age ≥ 18 years old, male or female not limited.
- Within 90 days, the gastroscopy and/or pathological results confirm the absence of gastric cancer.
- Patients must be able to fully understand the informed consent form and be able to personally sign it.
Exclusion Criteria:
- Severe heart, liver, kidney dysfunction, or mental illness.
- History of malignant tumors in the upper gastrointestinal tract.
- Pregnant women.
- Those with unclear pathology.
- Those with unsatisfactory sample retention (such as insufficient sample size).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Positive predictive value of early diagnosis of gastric cancer
Time Frame: baseline
|
baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2025
Primary Completion (Estimated)
October 1, 2027
Study Completion (Estimated)
December 30, 2027
Study Registration Dates
First Submitted
June 21, 2025
First Submitted That Met QC Criteria
December 30, 2025
First Posted (Actual)
December 31, 2025
Study Record Updates
Last Update Posted (Actual)
December 31, 2025
Last Update Submitted That Met QC Criteria
December 30, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2410-Exp092-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.